MX2020003045A - Inhibidor de mpges-1 para el tratamiento de dolor de osteoartritis. - Google Patents
Inhibidor de mpges-1 para el tratamiento de dolor de osteoartritis.Info
- Publication number
- MX2020003045A MX2020003045A MX2020003045A MX2020003045A MX2020003045A MX 2020003045 A MX2020003045 A MX 2020003045A MX 2020003045 A MX2020003045 A MX 2020003045A MX 2020003045 A MX2020003045 A MX 2020003045A MX 2020003045 A MX2020003045 A MX 2020003045A
- Authority
- MX
- Mexico
- Prior art keywords
- mpges
- inhibitor
- osteoarthritis pain
- treatment
- subject
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 201000008482 osteoarthritis Diseases 0.000 title abstract 3
- 101710096361 Prostaglandin E synthase Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 230000003228 microsomal effect Effects 0.000 abstract 1
- -1 triazolone compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención hace referencia a un inhibidor de la prostaglandina E sintasa microsomal 1 (mPGES-1) para el tratamiento del dolor por osteoartritis en un sujeto. Por ejemplo, la presente invención hace referencia a un método para tratar el dolor moderado de osteoartritis en un sujeto que lo necesita mediante la administración oral al sujeto de un compuesto de triazolona sustituido como un inhibidor de mPGES-1. La presente invención también hace referencia a composiciones farmacéuticas que comprenden el inhibidor de mPGES-1, y a procesos para preparar tales composiciones farmacéuticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721033369 | 2017-09-20 | ||
| IN201721042452 | 2017-11-27 | ||
| PCT/IB2018/057244 WO2019058295A1 (en) | 2017-09-20 | 2018-09-20 | INHIBITOR OF MPGES-1 FOR THE TREATMENT OF ARTHROSIS PAIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003045A true MX2020003045A (es) | 2020-09-14 |
Family
ID=63794565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003045A MX2020003045A (es) | 2017-09-20 | 2018-09-20 | Inhibidor de mpges-1 para el tratamiento de dolor de osteoartritis. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10758517B2 (es) |
| EP (1) | EP3684356A1 (es) |
| JP (1) | JP2020534310A (es) |
| KR (1) | KR20200094132A (es) |
| CN (1) | CN111526875A (es) |
| AU (1) | AU2018338045A1 (es) |
| BR (1) | BR112020005573A2 (es) |
| CA (1) | CA3076480A1 (es) |
| CO (1) | CO2020004599A2 (es) |
| IL (1) | IL273364A (es) |
| MX (1) | MX2020003045A (es) |
| PE (1) | PE20212078A1 (es) |
| PH (1) | PH12020500393A1 (es) |
| SG (1) | SG11202002307TA (es) |
| WO (1) | WO2019058295A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12285541B2 (en) * | 2023-01-26 | 2025-04-29 | Insignia Pharmaceuticals, Llc | Pharmaceutical compositions for treating osteoarthritis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2016016861A1 (en) * | 2014-08-01 | 2016-02-04 | Glenmark Pharmaceuticals S.A. | Nanoparticulate formulation comprising a mpges-1 inhibitor |
-
2018
- 2018-09-20 MX MX2020003045A patent/MX2020003045A/es unknown
- 2018-09-20 EP EP18783124.3A patent/EP3684356A1/en not_active Withdrawn
- 2018-09-20 WO PCT/IB2018/057244 patent/WO2019058295A1/en not_active Ceased
- 2018-09-20 CN CN201880060774.XA patent/CN111526875A/zh active Pending
- 2018-09-20 AU AU2018338045A patent/AU2018338045A1/en not_active Abandoned
- 2018-09-20 KR KR1020207011280A patent/KR20200094132A/ko not_active Withdrawn
- 2018-09-20 JP JP2020516479A patent/JP2020534310A/ja active Pending
- 2018-09-20 CA CA3076480A patent/CA3076480A1/en not_active Abandoned
- 2018-09-20 SG SG11202002307TA patent/SG11202002307TA/en unknown
- 2018-09-20 PE PE2020000568A patent/PE20212078A1/es unknown
- 2018-09-20 BR BR112020005573-5A patent/BR112020005573A2/pt not_active Application Discontinuation
-
2019
- 2019-02-21 US US16/282,125 patent/US10758517B2/en not_active Expired - Fee Related
-
2020
- 2020-02-27 PH PH12020500393A patent/PH12020500393A1/en unknown
- 2020-03-17 IL IL273364A patent/IL273364A/en unknown
- 2020-04-16 CO CONC2020/0004599A patent/CO2020004599A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019058295A1 (en) | 2019-03-28 |
| KR20200094132A (ko) | 2020-08-06 |
| US10758517B2 (en) | 2020-09-01 |
| JP2020534310A (ja) | 2020-11-26 |
| EP3684356A1 (en) | 2020-07-29 |
| US20190175562A1 (en) | 2019-06-13 |
| CO2020004599A2 (es) | 2020-07-31 |
| PE20212078A1 (es) | 2021-10-28 |
| PH12020500393A1 (en) | 2021-01-04 |
| CN111526875A (zh) | 2020-08-11 |
| CA3076480A1 (en) | 2019-03-28 |
| SG11202002307TA (en) | 2020-04-29 |
| IL273364A (en) | 2020-05-31 |
| AU2018338045A1 (en) | 2020-04-02 |
| BR112020005573A2 (pt) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| NZ730724A (en) | Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| MY202884A (en) | Compounds useful in hiv therapy | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| TN2018000372A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2019004822A (es) | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. | |
| PH12020500393A1 (en) | Mpges-1 inhibitor for the treatment of osteoarthritis pain | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus |